NL4-3 mCherry Luciferase Citations (9)
Originally described in: A flexible model of HIV-1 latency permitting evaluation of many primary CD4 T-cell reservoirs.Lassen KG, Hebbeler AM, Bhattacharyya D, Lobritz MA, Greene WC PLoS One. 2012;7(1):e30176. doi: 10.1371/journal.pone.0030176. Epub 2012 Jan 24. PubMed Journal
Articles Citing NL4-3 mCherry Luciferase
| Articles |
|---|
| Nuclear RNA surveillance complexes silence HIV-1 transcription. Contreras X, Salifou K, Sanchez G, Helsmoortel M, Beyne E, Bluy L, Pelletier S, Rousset E, Rouquier S, Kiernan R. PLoS Pathog. 2018 Mar 19;14(3):e1006950. doi: 10.1371/journal.ppat.1006950. eCollection 2018 Mar. PubMed |
| Selection, Expansion, and Unique Pretreatment of Allogeneic Human Natural Killer Cells with Anti-CD38 Monoclonal Antibody for Efficient Multiple Myeloma Treatment. Motais B, Charvatova S, Walek Z, Hrdinka M, Smolarczyk R, Cichon T, Czapla J, Giebel S, Simicek M, Jelinek T, Sevcikova T, Sobotka J, Koristek Z, Hajek R, Bago JR. Cells. 2021 Apr 21;10(5). pii: cells10050967. doi: 10.3390/cells10050967. PubMed |
| Heparan Sulfate Facilitates Spike Protein-Mediated SARS-CoV-2 Host Cell Invasion and Contributes to Increased Infection of SARS-CoV-2 G614 Mutant and in Lung Cancer. Yue J, Jin W, Yang H, Faulkner J, Song X, Qiu H, Teng M, Azadi P, Zhang F, Linhardt RJ, Wang L. Front Mol Biosci. 2021 Jun 11;8:649575. doi: 10.3389/fmolb.2021.649575. eCollection 2021. PubMed |
| Neutralizing Antibodies to SARS-CoV-2 Selected from a Human Antibody Library Constructed Decades Ago. Qiang M, Ma P, Li Y, Liu H, Harding A, Min C, Wang F, Liu L, Yuan M, Ji Q, Tao P, Shi X, Li Z, Li T, Wang X, Zhang Y, Wu NC, Lee CD, Zhu X, Gilbert-Jaramillo J, Zhang C, Saxena A, Huang X, Wang H, James W, Dwek RA, Wilson IA, Yang G, Lerner RA. Adv Sci (Weinh). 2022 Jan;9(1):e2102181. doi: 10.1002/advs.202102181. Epub 2021 Oct 29. PubMed |
| Developing an Effective Peptide-Based Vaccine for COVID-19: Preliminary Studies in Mice Models. Yang H, Cao J, Lin X, Yue J, Zieneldien T, Kim J, Wang L, Fang J, Huang RP, Bai Y, Sneed K, Cao C. Viruses. 2022 Feb 22;14(3). pii: v14030449. doi: 10.3390/v14030449. PubMed |
Monospecific and bispecific monoclonal SARS-CoV-2 neutralizing antibodies that maintain potency against B.1.617.
Peng L, Hu Y, Mankowski MC, Ren P, Chen RE, Wei J, Zhao M, Li T, Tripler T, Ye L, Chow RD, Fang Z, Wu C, Dong MB, Cook M, Wang G, Clark P, Nelson B, Klein D, Sutton R, Diamond MS, Wilen CB, Xiong Y, Chen S.
Nat Commun. 2022 Mar 28;13(1):1638. doi: 10.1038/s41467-022-29288-3.
PubMed
Associated Plasmids |
| SARS-CoV-2 pan-variant inhibitory peptides deter S1-ACE2 interaction and neutralize delta and omicron pseudoviruses. Shah M, Ung Moon S, Hyun Kim J, Thanh Thao T, Goo Woo H. Comput Struct Biotechnol J. 2022;20:2042-2056. doi: 10.1016/j.csbj.2022.04.030. Epub 2022 Apr 26. PubMed |
| Production and characterization of lentivirus vector-based SARS-CoV-2 pseudoviruses with dual reporters: Evaluation of anti-SARS-CoV-2 viral effect of Korean Red Ginseng. Moon J, Jung Y, Moon S, Hwang J, Kim S, Kim MS, Yoon JH, Kim K, Park Y, Cho JY, Kweon DH. J Ginseng Res. 2023 Jan;47(1):123-132. doi: 10.1016/j.jgr.2022.07.003. Epub 2022 Jul 15. PubMed |
| Novel Local "Off-the-Shelf" Immunotherapy for the Treatment of Myeloma Bone Disease. Charvatova S, Motais B, Czapla J, Cichon T, Smolarczyk R, Walek Z, Giebel S, Hajek R, Bago JR. Cells. 2023 Jan 30;12(3):448. doi: 10.3390/cells12030448. PubMed |
If you have published an article using this material, please email us at [email protected] to have your article added to this page.